In the US, Alirocumab (alirocumab systemic) is a member of the drug class PCSK9 inhibitors and is used to treat Cardiovascular Risk Reduction, High Cholesterol, High Cholesterol - Familial Heterozygous and High Cholesterol - Familial Homozygous.
CAS registry number (Chemical Abstracts Service)
Lipid lowering agent
Lipid lowering agent for the treatment of homozygous familial hypercholesterolemia
Immunoglobulin G1-kappa, anti-[Homo sapiensPCSK9 (propotein convertase subtilisin/kexin type 9)], Homo sapiensmonoclonal antibody;gamma1 haevy chain (1-447)[Homo sapiensVH (IGHV3-23*04 (89.80%) -(IGHD)-IGHJ2*01 [8.8.11](1-118) -IGHG1*01 CHS K2>del (119-44 (WHO)
- Alirocumabum (Latin)
- Alirocumab (German)
- Alirocumab (French)
- Alirocumab (Spanish)
- Alirocumab (OS: USAN)
- Alirocumab (Genetical Recombination) (OS: JAN)
- REGN727 (IS)
- UNII-PP0SHH6V16 (IS)
Sanofi, United Kingdom; Sanofi-Aventis, Germany
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.